A Relaxin receptor agonist drug (RRA01) for the acute heart failure treatment is developed by the...

A Relaxin receptor agonist drug (RRA01) for the acute heart failure treatment is developed by the Sunny Pharmaceutical Company. It is a publicly traded company. The reduction of cardiovascular death (mortality) was used as the end point (results of the research) for this investigation. The null hypothesis is “there is no difference in the cardiovascular mortality reduction between patients who received RRA01 (treatment group) and those who did not receive RRA01 (control group). Discuss the impact (on the company and/or on the patients) of the following two possible clinical trial results to the Sunny Pharmaceutical Company, staff of the company, and the patients. 1. p = 0.002 as the hypothesis test results 2. p = 0.3 as the hypothesis test results.

Expert Solution

A Relaxin receptor agonist drug (RRA01) for the acute heart failure treatment is developed by the Sunny Pharmaceutical Company. It is a publicly traded company. The reduction of cardiovascular death (mortality) was used as the end point (results of the research) for this investigation. The null hypothesis is “there is no difference in the cardiovascular mortality reduction between patients who received RRA01 (treatment group) and those who did not receive RRA01 (control group). Discuss the impact (on the company and/or on the patients) of the following two possible clinical trial results to the Sunny Pharmaceutical Company, staff of the company, and the patients.

1. p = 0.002 as the hypothesis test results

P=0.002 shows that there is significant cardiovascular mortality reduction between patients who received RRA01 (treatment group) and those who did not receive RRA01 (control group). Since the significant result the staff of the company should promote the drug in the market. The patients should be prescribed this drug, because it is more effective..

2. p = 0.3 as the hypothesis test results.

P=0.3 shows that there is no significant cardiovascular mortality reduction between patients who received RRA01 (treatment group) and those who did not receive RRA01 (control group). Since the result is not significant the staff of the company should improve the drug. The patients not to prescribed this drug, because it is not more effective than standard drugs.

.

milcah answered 3 weeks ago

outline standard drug regimenfor the treatment of heart failure ?

Drug: labetalol Molecular target(s) of the drug? Is the drug a receptor agonist? If yes, what...

Drug: labetalol Molecular target(s) of the drug? Is the drug a receptor agonist? If yes, what receptor(s)? Is the drug a receptor antagonist? If yes, what receptor(s) Does the drug cause vascular smooth muscle contraction or relaxation? Will the drug inhibit a vascular smooth muscle contraction induced by phenylephrine? If yes, the action via which one of the following three mechanisms: (1) the drug inhibits the binding of phenylephrine to its receptor; OR (2) the drug inhibits the signal transduction...

Select a drug example for each the agonist, partial agonist, antagonist, and inverse agonist and explain...

Select a drug example for each the agonist, partial agonist, antagonist, and inverse agonist and explain if the resultant action is fast onset (seconds to minutes) or slow onset (weeks) and how do you know? How could environment effect response to these drug examples?

Maria Perez is a patient arriving from the Emergency Department (ED) with acute heart failure and...

Maria Perez is a patient arriving from the Emergency Department (ED) with acute heart failure and confusion. Betty, the licensed practical nurse/licensed vocational nurse (LPN/LVN) who receives the call from the ED, recognizes the patient’s name and volunteers to take Maria as a patient. While getting Maria settled, Betty recognizes that this patient needs more care than she expected. SCENE 1: The cardiac care unit receives a call from the ED about a new admission: Maria Perez, a patient with...

Explain and compare each: Right heart failure Left heart failure Mixed Heart Failure

Binding of an agonist to an adrenergic GPCR receptor results in: A. The GalphaS subunit dissociating...

Binding of an agonist to an adrenergic GPCR receptor results in: A. The GalphaS subunit dissociating from the Gbeta-Ggamma subunits. B. The Gbeta subunit dissociating from the GalphaS-Ggamma subunits. C. The Ggamma-subunit dissociating from the GalphaS-Gbeta subunits. D. None of the above are correct. E. All of the above are correct. mTORC signaling occurs when: A. the cell has an energy deficit and requires more nutrients. B. the cell has an adequate supply of nutrients and is in a high-energy...

Consider a new drug being developed for the treatment of a relatively common indication, such as...

Consider a new drug being developed for the treatment of a relatively common indication, such as diabetes mellitus or high blood pressure. In vitro and preclinical studies indicate the compound is extensively metabolized, primarily by CYP3A and partially by CYP2C19. The compound does not appear to be an inducer or inhibitor of any CYP450 enzymes, but it is a potential inhibitor of P-glycoprotein (P-gp). What in vivo drug-drug interaction (DDI) studies should the company developing the compound consider? A. A...

Overview of heart failure

George Brown, 72 years of age, is a male patient who is admitted with the diagnosis of acute pulmonary edema secondary to acute left ventricular heart failure.

George Brown, 72 years of age, is a male patient who is admitted with the diagnosis of acute pulmonary edema secondary to acute left ventricular heart failure. The patient has a history of coronary artery disease that has been treated medically. The patient is anxious, pale, cold, clammy, and dyspneic. The vital signs are: blood pressure 88/50 mm Hg, heart rate 110 bpm, respiratory rate 32 breaths/min, and temperature 97°F. There are bubbling crackles and wheezing throughout the lung fields...

(1) Explain Acute versus chronic conditions with patient with heart failure (2) Tissue integrity: Explain venous...

(1) Explain Acute versus chronic conditions with patient with heart failure (2) Tissue integrity: Explain venous stasis ulcer (3) What is the cause of leukemia?

Question